---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-105024"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:19:56.375857+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology Q2 net loss widens to $66.1M; FDA sets Nov 30 PDUFA for ziftomenib NDA

## Summary
- Net loss $66.1M in Q2 2025 vs $50.8M in Q2 2024; collaboration revenue $15.3M from Kyowa Kirin.
- FDA Priority Review for ziftomenib NDA; PDUFA target action date Nov 30, 2025.
- Cash, equivalents and investments $630.7M as of June 30; expected to fund operations into 2027, plus Kyowa Kirin funding.
- Phase 3 KOMET-017 trials and first KO-2806/FTI data expected in 2H 2025 at ESMO.

## SEC filing metadata
- accession: 0000950170-25-105024
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000095017025105024/0000950170-25-105024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000095017025105024/kura-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-105024
- JSON: https://secwatch.observer/filing/0000950170-25-105024.json
- Plain text: https://secwatch.observer/filing/0000950170-25-105024.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.